• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Levosimendan does not improve sepsis-related outcomes: The LeoPARDS trial

byDavid ArsaniousandShaidah Deghan, MSc. MD
October 29, 2016
in Emergency, Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. No significant difference was observed in 28-day mean SOFA score or overall mortality in patients who received levosimendan vs. controls.

2. A significant increase in successful weaning from mechanical ventilation was observed in controls vs. patients who received levosimendan.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Septic shock is a state of life threatening end-organ damage due to severe systemic hypotension and low cardiac output. While catecholamines are often among the first-line pharmacologic agents in the treatment of septic shock, they are not without significant side effect profiles in such unstable patients. For this reason, the calcium sensitizer levosimendan has been investigated for the treatment of septic shock due its action as a positive cardiac inotrope that minimally increases myocardial oxygen demand.

The Levosimendan for the prevention of Acute Organ Dysfunction in Sepsis (LeoPARDS) trial, was a double-blind, randomized clinical trial to test the effects of addition of levosimendan to standard care for septic shock. The primary trial outcome was mean 28-day (or sooner) Sequential Organ Failure Assessment (SOFA) score. Secondary outcomes included 28-day overall mortality and time to weaning of mechanical ventilation. For the primary outcome, a nonsignificant difference was observed between the levosimendan and control groups. For the mentioned secondary outcomes, a nonsignificant difference was observed between the groups in overall mortality and a significant difference was observed in ventilator weaning in favor of the control group. This study draws strength from thorough analyses of the varying primary and secondary outcomes, such as reporting of individual component SOFA scores for five organ systems and of survival and toxicity outcomes at differing points in the hospital courses. The generalizability of the study appears to be limited by its use of indistinct definitions of standard therapy for septic shock.

Click to read the study, published today in NEJM

Relevant Reading: Levosimendan: current data, clinical use and future development

RELATED REPORTS

#VisualAbstract: Restriction of Intravenous Fluids in ICU Patients with Septic Shock

#VisualAbstract: Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients

Intravenous fluid restriction does not improve septic shock outcomes

In-Depth [randomized controlled trial]: Patients in this study were randomized in a 1:1 ratio to receive either one 24-hour infusion of levosimendan (n = 259) or placebo (n = 257). The mean difference in the primary outcome, 28-day SOFA score, between the levosimendan group vs. the control group was 0.61 (95%CI −0.07 to 1.29; p = 0.053). All secondary outcomes demonstrated nonsignificant between group differences with the only exceptions being supraventricular tachyarrhythmia, 3.1% in the levosimendan group vs 0.4% in the placebo group, (absolute difference 2.7%; 95%CI 0.1 to 5.3, p = 0.04) and successful weaning of mechanical ventilation by 28 days in favor of the control group (HR 0.77; 95%CI 0.60 to 0.97; p = 0.03). Notable nonsignificant different secondary outcomes included overall mortality at 28 days of 34.5% in the levosimendan group vs. 30.9% in the placebo group (absolute difference 3.6%; 95%CI −4.5 to 11.7; p = 0.43).

Image: CC/Wiki

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: intensive caresepsis
Previous Post

Pediatric screening for family hypercholesterolemia is feasible and efficacious

Next Post

The ICAP trial: Colchicine in acute pericarditis [Classics Series]

RelatedReports

#VisualAbstract: Restriction of Intravenous Fluids in ICU Patients with Septic Shock
StudyGraphics

#VisualAbstract: Restriction of Intravenous Fluids in ICU Patients with Septic Shock

July 8, 2022
#VisualAbstract: Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients
StudyGraphics

#VisualAbstract: Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients

July 7, 2022
Hypotonic IVF linked to increased risk of hyponatremia
Emergency

Intravenous fluid restriction does not improve septic shock outcomes

June 27, 2022
Emergency

Intravenous vitamin C increases mortality and organ dysfunction in sepsis patients

June 27, 2022
Next Post
Adverse pregnancy outcomes associated with thrombophilias [Classics Series]

The ICAP trial: Colchicine in acute pericarditis [Classics Series]

Dacomitinib may be effective in EGFR-associated lung cancer

Blocking fatty acid synthesis may curb lung cancer growth [PreClinical]

Pediatric DKA associated with recent acute care visits

New peptide-modified hydrogel developed for diabetic wound healing [PreClinical]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Endoscopic sleeve gastroscopy effective for excess weight loss in type 1 and 2 obesity
  • #VisualAbstract: Early time-restricted eating was more effective for weight loss than eating over 12-hour window
  • Removal of asymptomatic kidney stones reduces risk of relapse
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.